Medicus Pharma Ltd. Common Stock
MDCXNASDAQHealthcare● Active
$0.34
$-0.01(-3.94%)
Market Cap$7410165
P/E Ratio—
52W High$3.69
52W Low$0.25
Medicus Pharma Ltd. Common Stock (MDCX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MDCX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.31
Est. -$0.18 · -72.2%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS
MDCX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.14 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 14, 2026 | -$0.18 | -$0.31 | -72.2% | — | — | — |
| ▼ Q1 FY2026 | Mar 25, 2026 | -$0.32 | -$0.82 | -156.3% | — | — | — |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$0.38 | -$0.65 | -71.0% | — | — | — |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.39 | -$0.43 | -10.3% | — | — | — |
| ▼ Q2 FY2025 | May 12, 2025 | -$0.23 | -$0.42 | -82.6% | — | — | — |
| ▲ Q1 FY2025 | Mar 28, 2025 | -$0.32 | -$0.18 | +43.8% | — | — | — |
| ▼ Q4 FY2024 | Nov 22, 2024 | -$0.22 | -$0.31 | -40.6% | — | — | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.14
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
-$0.31
EPS Est.
-$0.18
EPS Surpr.
-72.2%
Revenue
—
Q1 FY2026
Mar 25, 2026Miss
EPS Actual
-$0.82
EPS Est.
-$0.32
EPS Surpr.
-156.3%
Revenue
—
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$0.65
EPS Est.
-$0.38
EPS Surpr.
-71.0%
Revenue
—
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$0.43
EPS Est.
-$0.39
EPS Surpr.
-10.3%
Revenue
—
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$0.42
EPS Est.
-$0.23
EPS Surpr.
-82.6%
Revenue
—
Q1 FY2025
Mar 28, 2025Beat
EPS Actual
-$0.18
EPS Est.
-$0.32
EPS Surpr.
+43.8%
Revenue
—
Q4 FY2024
Nov 22, 2024Miss
EPS Actual
-$0.31
EPS Est.
-$0.22
EPS Surpr.
-40.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.01 | $0.01 | $0.01 | 1 |
| Q3 FY2028 | $0.01 | $0.01 | $0.01 | 1 |
| Q2 FY2028 | $0.01 | $0.01 | $0.01 | 1 |
| Q1 FY2028 | $0.01 | $0.01 | $0.01 | 1 |
| Q4 FY2027 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Q3 FY2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -72.2% | $0.32 | $0.34 | +5.28% |
| ▼ Q1 FY2026 | Mar 25, 2026 | -156.3% | $0.49 | $0.49 | +1.00% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -71.0% | $2.26 | $2.20 | -2.65% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -10.3% | $1.97 | $1.97 | +0.00% |
| ▼ Q2 FY2025 | May 12, 2025 | -82.6% | $4.59 | $4.86 | +5.88% |
| ▲ Q1 FY2025 | Mar 28, 2025 | +43.8% | $3.30 | $3.13 | -5.15% |
| ▼ Q4 FY2024 | Nov 22, 2024 | -40.6% | $2.20 | $1.92 | -12.73% |
| ▼ Q3 FY2024 | Aug 22, 2024 | -126.7% | No price data | $2.65 | — |
Q2 FY2026+5.28%
Report Date
May 14, 2026
EPS Beat/Miss
-72.2%
Price Before
$0.32
Price After
$0.34
Q1 FY2026+1.00%
Report Date
Mar 25, 2026
EPS Beat/Miss
-156.3%
Price Before
$0.49
Price After
$0.49
Q4 FY2025-2.65%
Report Date
Nov 14, 2025
EPS Beat/Miss
-71.0%
Price Before
$2.26
Price After
$2.20
Q3 FY2025+0.00%
Report Date
Aug 11, 2025
EPS Beat/Miss
-10.3%
Price Before
$1.97
Price After
$1.97
Q2 FY2025+5.88%
Report Date
May 12, 2025
EPS Beat/Miss
-82.6%
Price Before
$4.59
Price After
$4.86
Q1 FY2025-5.15%
Report Date
Mar 28, 2025
EPS Beat/Miss
+43.8%
Price Before
$3.30
Price After
$3.13
Q4 FY2024-12.73%
Report Date
Nov 22, 2024
EPS Beat/Miss
-40.6%
Price Before
$2.20
Price After
$1.92
Q3 FY2024—
Report Date
Aug 22, 2024
EPS Beat/Miss
-126.7%
Price Before
—
Price After
$2.65
Avg Beat Reaction-5.15%
Avg Miss Reaction-0.54%
Beat Rate1 / 8 quarters
Largest Move-12.73% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MDCX ends December
Medicus Pharma Ltd. Common Stock (MDCX) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.31 — missing the analyst consensus of $-0.18 by -72.2%. The next MDCX earnings date is expected around September 1, 2026.
Each quarter, investors track MDCX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MDCX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MDCX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MDCX earnings · 5 questionsMedicus Pharma Ltd. Common Stock's next earnings report is expected around September 1, 2026. MDCX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MDCX historically reports after market close (AMC).
MDCX earnings datewhen is MDCX earningsMDCX next earnings datewhen does MDCX report earningsMDCX earnings calendar
▸ Source: FMP · Medicus Pharma Ltd. Common Stock SEC filings · US GAAP · Medicus Pharma Ltd. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026